Acceptance and Commitment Therapy for Caregivers of Children with Genetic Syndromes
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if Acceptance and Commitment Therapy (ACT) can help caregivers of children with RASopathies (a group of genetic conditions affecting development) manage parenting stress more effectively. Participants will use an app to watch videos and answer questions as part of an 8-week program, which includes video sessions and coaching. It suits caregivers who live with a child diagnosed with a RASopathy at least half the time and experience moderate parenting stress. As an unphased trial, this study provides caregivers the chance to explore innovative support strategies tailored to their unique challenges.
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop your current medications. However, if you started taking psychiatric medication less than 4 weeks before enrolling, you may not be eligible.
What prior data suggests that Acceptance and Commitment Therapy (ACT) is safe for caregivers of children with genetic syndromes?
Research has shown that Acceptance and Commitment Therapy (ACT) is generally easy for caregivers to manage. One study found that ACT effectively reduced anxiety, depression, and stress in caregivers. This therapy helps individuals accept difficult thoughts and feelings, which can be particularly beneficial for those caring for children with long-term health issues.
Another study suggested that ACT could be even more effective when parents participate in the therapy. Although ACT is not a new treatment, it has shown promise in helping caregivers manage stress and improve their mental well-being. Overall, ACT appears to be a safe choice for caregivers seeking to better handle their challenges.12345Why are researchers excited about this trial?
Acceptance and Commitment Therapy (ACT) is unique because it focuses on helping caregivers manage stress and emotional challenges by promoting psychological flexibility. Unlike traditional therapy options that might center around problem-solving or symptom reduction, ACT encourages individuals to accept their feelings and commit to actions aligned with their values, even in the face of difficult emotions. Researchers are excited about this approach because it offers a holistic way to enhance the well-being of caregivers, which can ultimately lead to better support and outcomes for children with genetic syndromes. This method stands out by potentially improving mental health without the need for medication, making it an appealing option for those seeking non-pharmacological interventions.
What evidence suggests that Acceptance and Commitment Therapy (ACT) might be an effective treatment for parenting stress in caregivers of children with RASopathies?
Research has shown that Acceptance and Commitment Therapy (ACT) can help parents manage stress. One study found that ACT moderately reduced stress in parents of children with special needs. Another study demonstrated that ACT-based programs lowered parents' levels of depression, anxiety, and stress, while increasing their flexibility in handling challenges. Additionally, a specific ACT program significantly reduced parents' distress and improved their quality of life. In this trial, participants will receive ACT either immediately, after a waitlist period, or as part of an internal pilot to assess feasibility. These findings suggest that ACT could be a helpful tool for caregivers of children with genetic syndromes to better cope with parenting stress.36789
Who Is on the Research Team?
Staci M Peron, Ph.D.
Principal Investigator
National Cancer Institute (NCI)
Are You a Good Fit for This Trial?
This trial is for caregivers aged 18 or older who look after a child with a RASopathy syndrome, such as Neurofibromatosis or Noonan Syndrome. The child must live with them at least half the time. Caregivers should be experiencing moderate parenting stress and have access to technology like smartphones or computers for remote participation.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Internal Pilot Study
Initial cohort of 8 participants undergoes the ACT intervention to assess feasibility and acceptability
Randomized Controlled Trial (RCT)
Participants are randomized to either immediate intervention or waitlist control, with intervention starting after a 1-week baseline period
Follow-up
Participants are monitored for changes in parenting stress and other psychological measures post-intervention
What Are the Treatments Tested in This Trial?
Interventions
- Acceptance and Commitment Therapy (ACT)
Trial Overview
The study tests if Acceptance and Commitment Therapy (ACT) can reduce stress in caregivers of children with RASopathies. It's fully remote, using an app for videos and surveys. Participants will either start ACT immediately or after a waitlist period, determined by chance.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
Participants will begin their 1-week baseline EMA data collection period and then take part in intervention procedures immediately after enrollment to assess feasibility and acceptability.
Participants will begin their 1-week baseline EMA data collection period immediately after randomization and will begin receiving the 8-week intervention at the end of this week/beginning of the next week (depending on participant schedule).
After an initial 1-week baseline period for EMA data collection and 8 weeks of maintaining their usual routine (wait list period), participants will begin receiving the 8-week intervention.
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor
Published Research Related to This Trial
Citations
A Pilot Acceptance and Commitment Intervention for ...
This study examined the overall feasibility of conducting an intervention targeting stress in parents of children with genetic syndromes. Most parents ...
The effectiveness of Acceptance and Commitment Therapy ...
This meta-analysis confirmed that ACT moderately reduces stress among parents of children with special needs (SMD =– 0.42, 95% CI– 0.72 to– 0.12 ...
Acceptance and commitment therapy (ACT) for pediatric ...
ACT could be efficacious in the treatment of paediatric CNCP; furthermore, the inclusion of parents could lead to improved outcomes.
Effects of Acceptance and Commitment Therapy-based ...
The ACT-based interventions implemented with parents were effective in decreasing parents' levels of psychological inflexibility, depression, anxiety, stress, ...
5.
publications.aap.org
publications.aap.org/pediatrics/article/156/4/e2025071134/204188/Acceptance-and-Commitment-Therapy-for-Parents-ofAcceptance and Commitment Therapy for Parents of ...
Our study demonstrated that a 4-session ACT-based intervention significantly reduced parental psychological distress, improved QoL, enhanced ...
Acceptance and commitment therapy (ACT) for caregivers ...
Acceptance and commitment therapy (ACT) for caregivers of children with chronic conditions: A mixed methods systematic review (MMSR) of efficacy, process, and ...
Acceptance and commitment therapy among caregivers of ...
This study revealed that ACT intervention can effectively alleviate caregivers' anxiety, depression, and stress symptoms, which is consistent ...
(PDF) Acceptance and Commitment Therapy for Children ...
There is some evidence that ACT may help with depressive symptoms in children with SHCN and psychological inflexibility in their parents.
Acceptance and commitment therapy group protocol for ...
This pilot study evaluates the preliminary efficacy of a group-delivered caregiver treatment program, ACT for Parents of Anxious Children (ACT- ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.